Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15944161 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL15833652 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL15944160 | 0.99 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL15833651 | 0.98 | PRMT5 (0.96) | PRMT5WDR77 | |
| SCHEMBL15819561 | 0.93 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL15944170 | 0.92 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL15824915 | 0.92 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL19171119 | 0.89 | PRMT5 (0.80) | PRMT5WDR77 | |
| SCHEMBL17377016 | 0.89 | PRMT5 (0.80) | PRMT5WDR77 | |
| SCHEMBL17377206 | 0.89 | PRMT5 (0.80) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10479997-B2 | Compositions and methods for diagnosis and treatment of prostate cancer | NOVARTIS AG (CH) | 2019-11-19 | — | — | US | disclosed |
| US-20180186798-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2018-07-05 | — | — | US | disclosed |
| US-9908887-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170283807-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2017-10-05 | — | — | US | disclosed |
| US-9777008-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170114061-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20160214985-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-07-28 | — | — | US | disclosed |
| US-9388173-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2016-07-12 | — | — | US | disclosed |
| WO-2016089883-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2016-06-09 | — | — | WO | disclosed |
| US-20150344457-A1 | METHODS OF INHIBITING PRMT5 | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150133427-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-05-14 | — | — | US | disclosed |
| US-8906900-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140228343-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479997-B2 | Compositions and methods for diagnosis and treatment of prostate cancer | PRMT5, PRMT1, PRMT3 | PRMT5 1/4885WDR77 50/4885 |
| US-20150344457-A1 | METHODS OF INHIBITING PRMT5 | PRMT5, PRMT1, PRMT7 | PRMT5 1/4885WDR77 18/4885 |
| US-20150133427-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 48/4885 |
| US-20160214985-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 54/4885 |
| US-20140228343-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 48/4885 |
| US-20170114061-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 48/4885 |
| US-20180186798-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 48/4885 |
| US-20170283807-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | PRMT5, PRMT1, PRMT3 | PRMT5 1/4885WDR77 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.